A phase II study of denileukin diftitox (ONTAK) in patients with fludarabine refractory B-cell chronic lymphocytic leukemia.

被引：0
|
作者：
Lilly, M
Kuriakose, P
Turturro, F
Berdeja, J
Kerr, R
Surendranathan, A
Black, J
Frankel, A
机构：
[1] Loma Linda Univ, Loma Linda, CA 92350 USA
[2] Henry Ford Hosp, Detroit, MI 48202 USA
[3] Louisiana State Univ, Feist Weiller Canc Ctr, Shreveport, LA 71105 USA
[4] SW Reg Canc Ctr, Austin, TX USA
[5] Wake Forest Univ Hlth Sci, Winston Salem, NC USA
[6] Wake Forest Univ, Winston Salem, NC 27109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：597S / 597S
页数：1
相关论文
共 50 条
  • [21] Analysis of a phase II study of denileukin diftitox (ONTAK®) for B and T-cell non-Hodgkin's lymphoma.
    Dang, NH
    Hagemeister, FB
    Fayad, L
    Pro, B
    McLaughlin, P
    Romaguera, JE
    Samaniego, F
    Goy, A
    Wang, M
    Walker, PL
    Samuels, B
    Jones, D
    Rodriguez, MA
    BLOOD, 2003, 102 (11) : 303B - 303B
  • [22] Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
    Dang, Nam H.
    Fayad, Luis
    McLaughlin, Peter
    Romaguara, Jorge E.
    Hagemeister, Fredrick
    Goy, Andre
    Neelapu, Sattva
    Samaniego, Felipe
    Walker, Pamela L.
    Wang, Michael
    Rodriguez, Maria A.
    Tong, Ann T.
    Pro, Barbara
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) : 502 - 505
  • [23] A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer
    Gwin III, William R.
    Salazar, Lupe G.
    Dai, James Y.
    Higgins, Doreen
    Coveler, Andrew L.
    Childs, Jennifer S.
    Blancas, Rosie
    Dang, Yushe
    Reichow, Jessica
    Slota, Meredith
    Lu, Hailing
    Disis, Mary L.
    VACCINES, 2025, 13 (02)
  • [24] Increased angiogenesis in B-cell chronic lymphocytic leukemia.
    D'Arena, G
    Nunziata, G
    Vigliotti, ML
    Matera, R
    Coppola, G
    Carpinelli, N
    Tartarone, A
    Bisogno, RC
    Pistolese, G
    Di Renzo, N
    BLOOD, 2002, 100 (11) : 355B - 355B
  • [25] Chemokine plasma concentration in patients with B-cell chronic lymphocytic leukemia.
    Toro, Juan J.
    Choa-Bayona, Leonel
    Ahuja, Seema S.
    Quinones, Marlon P.
    Lee, Shuko
    Estrada, Carlos A.
    Freytes, Cesar O.
    BLOOD, 2006, 108 (11) : 326B - 327B
  • [26] DASATINIB PLUS FLUDARABINE IN PATIENTS WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A MULTICENTER PHASE II STUDY
    Kater, A.
    Spiering, M.
    Lui, R.
    Beckers, M.
    Tonino, S.
    Doorduijn, J.
    Daenen, S.
    Luijks, D.
    Eldering, E.
    van Oers, M.
    HAEMATOLOGICA, 2012, 97 : 304 - 304
  • [27] Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia
    Frankel, AE
    Surendranathan, A
    Black, JH
    White, A
    Ganjoo, K
    Cripe, LD
    CANCER, 2006, 106 (10) : 2158 - 2164
  • [28] Interim analysis of a phase II study of denileukin diftitox (Ontak) for relapsed/refractory T-cell non-Hodgkin's lymphoma.
    Dang, NH
    Pro, B
    Hagemeister, FB
    Jones, D
    Samuels, B
    Rodriguez, MA
    Goy, A
    Romaguera, JE
    Walker, PL
    Kwak, L
    Fayad, L
    BLOOD, 2004, 104 (11) : 722A - 722A
  • [29] Early estimates of safety for alemtuzumab combined with fludarabine for the treatment of relapsed/refractory B-cell chronic lymphocytic leukemia: Phase II multicenter study.
    Brown, Jennifer R.
    Stock, Wendy
    Katzen, Harvey I.
    Suarez, Agustin J.
    Lakhanpal, Shailendra
    Leis, Jose F.
    Flowers, Christopher
    BLOOD, 2006, 108 (11) : 336B - 336B
  • [30] Effectiveness of fludarabine in advanced B-cell chronic lymphocytic leukemia
    Montillo, M
    Tedeschi, A
    Delfini, C
    Olivieri, A
    DAdamo, F
    Leoni, P
    TUMORI, 1995, 81 (06) : 419 - 423
12345